Heron Therapeutics (NASDAQ:HRTX) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Heron Therapeutics (NASDAQ:HRTX) to a sell rating in a research note published on Saturday morning.

Other research analysts have also issued research reports about the company. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. HC Wainwright dropped their price target on Heron Therapeutics to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Needham & Company LLC cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $2.00.

Heron Therapeutics Trading Down 1.6%

Shares of HRTX opened at $0.49 on Friday. Heron Therapeutics has a 1-year low of $0.38 and a 1-year high of $1.57. The company has a current ratio of 2.53, a quick ratio of 1.51 and a debt-to-equity ratio of 17.51. The firm’s 50-day moving average price is $0.45 and its 200-day moving average price is $0.84. The firm has a market capitalization of $92.90 million, a price-to-earnings ratio of -2.73 and a beta of 1.65.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The company had revenue of $34.71 million during the quarter, compared to the consensus estimate of $36.72 million. Sell-side analysts anticipate that Heron Therapeutics will post -0.09 EPS for the current year.

Institutional Trading of Heron Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HRTX. Advisory Services Network LLC increased its position in Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 18,114 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics in the second quarter worth $26,000. R Squared Ltd bought a new stake in Heron Therapeutics in the first quarter worth $27,000. SG Americas Securities LLC grew its stake in shares of Heron Therapeutics by 39.1% in the fourth quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 6,858 shares during the last quarter. Finally, HORAN Wealth LLC purchased a new stake in shares of Heron Therapeutics in the first quarter worth $33,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.